Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=33 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Phase 2 N=37 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Median Progression-free Survival — 5 months
Phase 2 N=13 Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Phase 1 N=11 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Phase 3 N=131 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001
Phase 2 N=139 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Primary: Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT) — 16.7; 20.3; 18.5 percentage
Phase 2 N=86 A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T Cell Lymphoma
Primary: Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity…
Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Phase 2 N=5 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Phase 2 N=15 AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Lymphoma, T-Cell, Cutaneous
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Participants
Phase 1 N=18 Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Lymphoma, T-Cell, Cutaneous
Primary: Percentage of Patients With Complete or Partial Response as Measured by Change in Lesion Severity Using CAILS (Composite Assessment of Index Lesion Severity) — 27; 0…
Phase 1 N=23 Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants
Phase 1 N=12 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Phase 3 N=169 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Phase 3 N=21 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Primary: Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03…
Phase 2 N=137 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Phase 1 N=10 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
Phase 2 N=25 A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 2 N=4 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Phase 4 N=10 A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL — 60.0 percentage of participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=25 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Phase 2 N=102 A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Cutaneous T-cell Lymphoma
Primary: The Percent of Patients (Pts) With Objective Disease Response — 34 Percent of participants
Phase 2 N=58 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Independent Review Group — 86 percent of participants
Phase 3 N=129 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Lymphoma
Primary: Event-free Survival (EFS) — 74; 79 percentage of participants
Phase 2 N=18 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1